UK TRADING UPDATE SUMMARY: Fuller Smith & Turner Gets GBP100 Million
UK TRADING UPDATE SUMMARY: Fuller Smith & Turner Gets GBP100 Million
Read moreWed, 18th Mar 2020 15:33
UK TRADING UPDATE SUMMARY: Fuller Smith & Turner Gets GBP100 Million
Read moreMotif Bio Raises GBP650,000 To Strengthen Cash Position
Read more(Sharecast News) - Motif Bio, which has been reclassified as an AIM rule 15 cash shell, has raised a total of ?0.65m before expenses via a placing, it announced on Tuesday, through the issue of 162,500,000 ordinary shares with an institutional investor at a price of 0.4p each.
Read moreUK EXECUTIVE CHANGE SUMMARY: Scapa Healthcare, Industrial Heads Resign
Read moreMotif Bio Notes Hike In Share Price, Still Waiting For Sale Of Assets
Read moreMotif Bio Still Seeks To Make Acquisition As Working Capital Dwindles
Read moreMotif Bio And Hercules Amend Agreement To Facilitate Iclaprim Sale
Read moreMotif Bio To De-List From Nasdaq, Last Day Of Trading December 16
Read moreFive Motif Bio Non-Executive Directors Leave As Part Of Restructuring
Read moreMotif Bio Seals Clinical Research Firm Settlement Without Payments
Read more(Sharecast News) - Motif Bio announced on Monday that its subsidiary Motif BioSciences has reached an agreement with its former clinical research organisation to settle all obligations without further payment.
Read moreInvesco Cuts Stake In Biopharmaceutifcal Firm Motif Bio To 8.4%
Read more(Sharecast News) - Clinical-stage biopharmaceutical company Motif Bio has signed an agreement with the Walter Reed Army Institute of Research (WRAIR) to conduct pre-clinical testing to evaluate novel combinations with 'iclaprim', to improve safety and efficacy administered by a novel enhanced aerosol technology, it announced on Thursday.
Read moreMotif Bio Teams Up With US Forces To Look Into Iclaprim Use
Read more